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The APC I1307K Allele and BRCA-Associated Ovarian
Cancer Risk
To the Editor:
Most ovarian cancers attributable to autosomal domi-
nant genetic predisposition (∼10% of all cases) are as-
sociated with germ-line mutations in the BRCA1 or
BRCA2 genes (reviewed in Boyd 1998). Estimates of the
lifetime probability of developing ovarian cancer in as-
sociation with a BRCA mutation have a range of
16%–63% (Easton et al. 1995; Struewing et al. 1997;
Ford et al. 1998). This large variation in penetrance is
widely presumed to reflect the effects of various hor-
monal, environmental, and genetic modifiers, but few
such modifying factors have been identified. The use of
oral contraceptives was recently shown to substantially
reduce the risk of ovarian cancer in women with BRCA
mutations (Narod et al. 1998), yet it has been suggested
that bearing more offspring increases ovarian cancer risk
in BRCA1 carriers (Narod et al. 1995). The only genetic
modifier of BRCA penetrance yet shown is the HRAS1
locus, rare alleles of which are associated with an in-
creased risk of ovarian cancer in BRCA1 carriers (Phelan
et al. 1996).
The APC I1307K allele is a plausible candidate mod-
ifier of BRCA penetrance. First identified as a founder
mutation occurring in ∼6% of the Ashkenazi Jewish
population, the allele is present in a significantly higher
proportion of Jewish colorectal cancer patients and in
those with a family history of colorectal cancer (Laken
et al. 1997). The mechanism through which this allele
contributes to the development of colorectal cancer ap-
pears to involve the creation of a small hypermutable
region that undergoes somatic frameshift alterations
leading to APC inactivation and the initiation of tu-
morigenesis (Laken et al. 1997; Gryfe et al. 1998). Con-
sistent with this molecular genetic scenario are the well-
established roles of somatic APC mutations in the
initiation of sporadic colorectal cancer and germ-line
APC mutations in predisposition to familial adenoma-
tous polyposis (Kinzler and Vogelstein 1996).
Attempts to confirm and extend the original obser-
vation of APC I1307K-associated cancer risk in Ash-
kenazi Jews have produced inconsistent findings. Results
from one follow-up study implied that the APC I1307K
mutation alone does not significantly increase the risk
of colorectal cancer (Petrukhin et al. 1997). Recent data
from a large community-based study of Ashkenazi Jews
indicated that APC I1307K confers a modest but sig-
nificant risk of cancer in general but that odds ratios for
any particular cancer are not increased to statistically
significant levels (Woodage et al. 1998). Remarkably,
however, there is an apparent synergy between APC
I1307K and a mutant BRCA allele in relation to breast
cancer risk (Redston et al. 1998). Taken together, these
data suggest that APC I1307K may function as a low-
penetrance modifier of cancer risk in association with
high-penetrance cancer-predisposition alleles such as
BRCA1 or BRCA2. Thus, even though APC I1307K
alone does not appear to confer a substantial risk of
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Figure 1 Sequence analysis for detection of the APC I1307K
mutation. Shown is the sequence flanking APC codon 1307 from an
individual with the mutant I1307K allele (left) and from an individual
with the wild-type sequence only (right). The arrow indicates position
of the mutation.
Table 1
Frequency of APC I1307K in Ashkenazi Jewish Ovarian Cancer
Patients
Group
No. of I1307K
Carriers/Total No.
of Patients (%)
Odds
Ratioa
Confidence
Interval P
Controlsb 7/92 (7.6) 1.0 ) )
Cases:c
BRCA1 2/66 (3.0) .4 .1–1.9 .24
BRCA2 1/21 (4.8) .6 .1–5.2 .64
All BRCA 3/87 (3.4) .4 .1–1.7 .24
a As determined by logistic regression.
b Ashkenazi Jewish ovarian cancer patients without one of three
germ-line founder mutations in BRCA1 or BRCA2.
c Ashkenazi Jewish ovarian cancer patients with germ-line mu-
tations in BRCA1 (185delAG or 5382insC) or BRCA2 (6174delT).
ovarian cancer in the Ashkenazi Jewish population gen-
erally (Abrahamson et al. 1998; Woodage et al. 1998),
it remains possible that ovarian cancer risk may be in-
creased in carriers of both APC I1307K and a BRCA
mutation.
The purpose of this study was to use a case-case ep-
idemiological design to test the hypothesis that the car-
rier frequency of APC I1307K is higher in Ashkenazi
Jewish ovarian cancer patients with a deleterious germ-
line BRCA mutation than in Jewish ovarian cancer pa-
tients without a BRCA mutation, which would imply
that the mutant APC allele increases the penetrance of
BRCA mutations for ovarian cancer. The study was ap-
proved by the institutional review board of theMemorial
Sloan-Kettering Cancer Center. From a consecutive se-
ries of 933 ovarian cancer cases from this institution,
179 cases were identified in which the patient had in-
dicated a religious preference of Jewish. Genomic DNA
samples associated with these cases were then screened
for the presence of three founder mutations, 185delAG
and 5382insC in BRCA1 and 6174delT in BRCA2.
Eighty-seven BRCA-linked cancers were identified (des-
ignated as “cases”), 66 associated with BRCA1 (50 with
185delAG and 16 with 5382insC) and 21 associated
with BRCA2. An additional 92 patients (designated as
“controls”) were found not to carry any of these BRCA
mutations. Our procedures for the identification of these
BRCA founder mutations are described elsewhere in de-
tail (Rhei et al. 1998).
The status of APC codon 1307 was determined in all
cases and controls by PCR amplification of an 82-bp
product by means of the primers specified (Laken et al.
1997), followed by SSCP and direct sequence analyses
(fig. 1). Three (3.4%) of 87 BRCA-associated ovarian
cancer cases were found to harbor the APC I1307K al-
lele, as were 7 (7.6%) of 92 control subjects (table 1).
The frequency of APC I1307K found in controls (Jewish
ovarian cancer patients without germ-line BRCA mu-
tations) is nearly identical to the carrier frequency of
7.2% reported in a community-based survey of 15,000
Ashkenazi Jews (Woodage et al. 1998) and to the fre-
quency of 7.9% observed in a series of unselected Ash-
kenazi Jewish ovarian cancer patients (Abrahamson et
al. 1998). The lowered odds ratios (.4 to .6) found in
cases compared with controls were not statistically sig-
nificant and do not support the hypothesis that APC
I1307K confers an increased risk of ovarian cancer in
association with a germ-line BRCA mutation.
To determine whether the APC I1307K allele con-
tributed to ovarian tumorigenesis in those individuals
found to carry this mutation, genomic DNA from the
corresponding ovarian cancers was used as a template
for PCR amplification of a larger, 230-bp PCR product
by means of the primers specified (Laken et al. 1997).
None of the 10 ovarian cancer DNA samples examined
were found to harbor additional somatic mutations in
the hypermutable region surrounding APC I1307K, nor
did any of the tumors display evidence of loss of the
wild-type APC allele. These data indicate that the vari-
ant APC allele does not contribute to ovarian tumori-
genesis in affected carriers, consistent with the absence
of elevated ovarian cancer risk in carriers with BRCA
mutations.
These findings, together with those reported elsewhere
(Redston et al. 1998), suggest that APC I1307K is a
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significant genetic modifier of BRCA penetrance for
breast, but not ovarian, cancer. Of interest, in this con-
text, are observations from animal studies in which the
Min mouse, carrying a germ-line mutation in the murine
homologue of APC, is susceptible to mammary gland
tumorigenesis, in addition to that of the gastrointestinal
tract (Bilger et al. 1996). These data also support the
concept that genetic modifiers of BRCA penetrance are
likely to exert differential effects on breast and ovarian
tumorigenesis, as was found for the effect of rareHRAS1
alleles on ovarian, but not breast, cancer risk (Phelan et
al. 1996). As for many other genetic disorders, pene-
trance of dominant cancer-susceptibility alleles is likely
to depend on complex interactions between multiple ge-
netic and environmental modifying factors; furthermore,
those genetic factors that are found to affect BRCA pen-
etrance are not likely to be generalizable to both breast
and ovarian cancer risk.
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Germ-Line NF2 Mutations and Disease Severity in
Neurofibromatosis Type 2 Patients with Retinal
Abnormalities
To the Editor:
Neurofibromatosis type 2 (NF2; MIM 101000) is a clin-
ically variable disease caused by mutations in the NF2
tumor-suppressor gene. Commonmanifestations include
nervous system tumors and ocular abnormalities such
as presenile lens opacities and retinal abnormalities
